Skip to Content
Merck
All Photos(1)

Documents

SAB4600399

Sigma-Aldrich

Anti-Rabbit IgG (H+L), F(ab′)2 fragment, CF640R antibody produced in goat

~2 mg/mL, affinity isolated antibody, buffered aqueous solution

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.46

biological source

goat

conjugate

CF 640R conjugate

antibody form

affinity isolated antibody

antibody product type

secondary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

rabbit

concentration

~2 mg/mL

technique(s)

flow cytometry: 1-10 μg/mL
immunocytochemistry: suitable
immunohistochemistry: suitable
indirect ELISA: suitable
indirect immunofluorescence: 1-10 μg/mL
western blot: suitable

fluorescence

λex 642 nm; λem 662 nm

storage temp.

−20°C

target post-translational modification

unmodified

General description

This product is prepared by labeling high quality F(ab′)2 fragment of goat anti-rabbit IgG (H+L) with the far-red fluorescent dye CF640R. CF640R is a novel rhodamine-based dye spectrally very similar to Cy5 and Alexa Fluor 647. CF640R is much brighter than Cy5 and at least as bright as Alexa Fluor 647 when excited at 633 or 635 nm. However, the most important advantage of CF640R is its exceptional photostability. CF640R is far more photostable than the cyanine-based dyes Cy5 and Alexa Fluor 647. It is also more photostable than Atto 647N, a dye that has been extensively used in single molecule-based imaging. CF640R is also extremely water-soluble and pH-insensitive. These properties make CF640R a much better alternative to Cy5, Alexa Fluor 647 and other spectrally similar dyes.

Specificity

Binds with whole molecule rabbit IgG and the light chains of other rabbit immunoglobulins.

Immunogen

rabbit IgG(H+L)

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Supplied in phosphate buffered saline with 0.05% sodium azide, 50% glycerol and 0.2% BSA.

Preparation Note

Protect from light. The antibody solution should be gently mixed before use.

Legal Information

This product is distributed by Sigma-Aldrich Co. under the authorization of Biotium, Inc. This product is covered by one or more US patents and corresponding patent claims outside the US patents or pending applications owned or licensed by Biotium, Inc. including without limitation: 12/334,387; 12/607,915; 12/699,778; 12/850,578; 61/454,484. In consideration of the purchase price paid by the buyer, the buyer is hereby granted a limited, non-exclusive, non-transferable license to use only the purchased amount of the product solely for the buyer′s own internal research in a manner consistent with the accompanying product literature. Except as expressly granted herein, the sale of this product does not grant to or convey upon the buyer any license, expressly, by implication or estoppel, under any patent right or other intellectual property right of Biotium, Inc. Buyer shall not resell or transfer this product to any third party, or use the product for any commercial purposes, including without limitation, any diagnostic, therapeutic or prophylactic uses. This product is for research use only. Any other uses, including diagnostic uses, require a separate license from Biotium, Inc. For information on purchasing a license to use this product for purposes other than research, contact Biotium, Inc., 3159 Corporate Place, Hayward, CA 94545, Tel: (510) 265-1027. Fax: (510) 265-1352. Email: btinfo@biotium.com.
CF is a trademark of Biotium, Inc.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rui Qin et al.
ACS infectious diseases, 8(11), 2348-2361 (2022-10-12)
Better understanding of the molecular mechanisms underlying COVID-19 severity is desperately needed in current times. Although hyper-inflammation drives severe COVID-19, precise mechanisms triggering this cascade and what role glycosylation might play therein are unknown. Here we report the first high-throughput
Berta Alemany-Perna et al.
Movement disorders : official journal of the Movement Disorder Society, 39(7), 1099-1108 (2024-05-02)
Calcitriol, the active form of vitamin D (also known as 1,25-dihydroxycholecalciferol), improves the phenotype and increases frataxin levels in cell models of Friedreich ataxia (FRDA). Based on these results, we aimed measuring the effects of a calcitriol dose of 0.25
Marko Vidak et al.
International journal of molecular sciences, 19(5) (2018-05-08)
Glioblastoma (GB) is the most aggressive brain malignancy. Although some potential glioblastoma biomarkers have already been identified, there is a lack of cell membrane-bound biomarkers capable of distinguishing brain tissue from glioblastoma and/or glioblastoma stem cells (GSC), which are responsible
Alja Zottel et al.
Cancers, 15(3) (2023-02-12)
Glioblastoma (GBM) is the most common primary brain tumour and one of the deadliest cancers. In addition to late diagnosis and inadequate treatment, the extremely low survival rate is also due to the lack of appropriate therapeutic biomarkers and corresponding
Alja Zottel et al.
Therapeutic advances in medical oncology, 12, 1758835920915302-1758835920915302 (2020-05-20)
Glioblastoma is a particularly common and very aggressive primary brain tumour. One of the main causes of therapy failure is the presence of glioblastoma stem cells that are resistant to chemotherapy and radiotherapy, and that have the potential to form

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service